Cancer chemopreventive potential of the egyptian flaxseed oil in a rat colon carcinogenesis bioassay - implications for its mechanism of action

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 9, 2011, Pages 2385-2392

  Salim, Elsayed I ^a   Abou Shafey, Ahlam E ^a   Masoud, Ahmed A ^a   Elgendy, Salwa A ^a  

^a Tanta University   (Egypt)

Author keywords

Chemoprevention; Egyptian flaxseed oil; Mucin production; Rat colon model

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ANTINEOPLASTIC AGENT; LINSEED OIL;

ABERRANT CRYPT FOCUS; ADENOMA; ANIMAL; ARTICLE; BODY WEIGHT; CARCINOMA; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; COLON TUMOR; DRUG EFFECT; INTESTINE MUCOSA; MALE; ORGAN SIZE; PATHOLOGY; RAT; TUMOR VOLUME; WISTAR RAT;

1,2-DIMETHYLHYDRAZINE; ABERRANT CRYPT FOCI; ADENOMA; ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; CARCINOMA; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; INTESTINAL MUCOSA; LINSEED OIL; MALE; ORGAN SIZE; RATS; RATS, WISTAR; TUMOR BURDEN;

EID: 84866288790     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Adolphe JL, Whiting SJ, Juurlink BH, et al (2010). Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. Br J Nutr, 103, 929-38.
2. Allain CC, Poon LS, Chan CS, et al (1974). Enzymatic determination of total serum cholesterol. Clin Chem, 20, 470-5.
3. Allen A, Hutton DA, Pearson JP (1998). The MUC2 gene product: a human intestinal mucin. Int J Biochem Cell Biol, 30, 797-801.
4. Augenlicht LH, AnthonyGM, Church TL, et al (1999). Short-chain fatty acid metabolism, apoptosis, and APC- initiated tumorigenesis in the mouse gastrointestinal mucosa. Cancer Res, 59, 6005-9.
5. Bara J, Forgue-Lafitte ME, et al (2003). Abnormal expression of gastric mucin in human and rat aberrant crypt foci during colon carcinogenesis. Tumor Biol, 24, 109-15.
6. Basch E, Bent S, Collins J, et al (2007). Flax and flaxseeds Oil (Linum usitatissimum): A Review by the Natural Standard Research Collaboration. J Soc Integr Oncol, 5, 92-105.
7. Bhathena SJ (2003). Flaxseeds outperforms soy in reducing cholesterol and liver fat levels. Am Coll Nutr, 22, 157-64.
8. Bucolo G, David H (1973). Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem, 19, 476-782.
9. Campbell AP (2003). Flax facts. A grain for good health. Diabetes Self Manage, 18, 20-2.
10. Caygill CP, Charlett A, Hill MJ (1996). Fat, fish, fish oil and cancer. Br J Cancer, 74, 159-64.
11. Corfield AP, Warren BF (1996). Mucus glycoproteins and their role in colorectal disease. J Pathol, 180, 8-17.
12. Corfield AP, Longman RJ, Sylvester PA (2000). Mucins and mucosal protection in the gastrointestinal tract: New prospects for mucins in the pathology of gastrointestinal disease. Gut, 47, 589-94.
13. Corpet DE, Tache S (2002). Most effective colon cancer chemopreventive agents in rats: A systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer, 43, 1-21.
14. Cunnane SC, Hamadeh MJ, Liede AC, et al (1995). Nutritional attributes of traditional flaxseeds in healthy young adults. Am J Clin Nutr, 61, 62-8.
15. El-Najjar N, Saliba N, Talhouk S, et al (2007). Onopordum cynarocephalum induces apoptosis and protects against 1,2 dimethylhydrazine-induced colon cancer. Oncol Rep, 17, 1517-23.
16. Fang HM, Mei Q, Xu JM (2007). 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. World J Gastroenterol, 13, 2872-7.
17. Fearon ER, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759-67.
18. Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr
19. Fernandes CR, Turatti A, Gouvea DR, et al (2011). The protective role of Lychnophora ericoides Mart. (Brazilian arnica) in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. Nutr Cancer, 63, 593-9.
20. Giada Mde L (2010). Food applications for flaxseeds and its components: products and processing. Rec Pat Food Nutr Agric, 2, 181-6.
21. Harper CR, Edwards MJ, Defilipis AP (2006). Flaxseeds oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans. J Nutr, 136, 83-7.
22. Harris A, Reid C (1997). Cystic fibrosis and mucins. J Med Genet, 35, 82-3.
23. Henry RJ (1964). Clinical Chemistry, Harper & Row Publishers, New York, P. 181.
24. Hong MY, Bancroft LK, Turner ND, et al (2005). Fish oil decreases oxidative DNA damage by enhancing apoptosis in rat colon. Nutr Cancer, 52, 166-75.
25. Hu C, Yuan YV, Kitts DD (2007). Antioxidant activities of the flaxseeds lignan secoisolariciresinol diglucoside, its aglycone secoisolariciresinol and the mammalian lignans enterodiol and enterolactone in vitro. Food Chem Toxicol, 45, 2219-27.
26. Jenab M, Thompson LU (1996). The influence of flaxseeds and lignans on colon carcinogenesis and beta-glucuronidase activity. Carcinogenesis, 6, 1343-8.
27. Kinzler KW, Vogelstein B (1996). Lessons from hereditary colon cancer. Cell, 87, 159-70.
28. Kim KM, Lee EJ, Ha S et al (2011). Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol, 35, 1274-86.
29. Lamblin F, Hano C, Fliniaux O, et al (2008). Interest of lignans in prevention and treatment of cancers. Med Sci, 24, 511-9 (in French).
30. Losi L, Roncucci L, Digregorio C, et al (1996). K-ras and P53 mutation in human colorectal aberrant crypt foci. J Pathol, 128, 259-63.
31. Moniaux N, Escande R, Porchel N, et al (2001). Structural organization and classification of the human mucin genes. Front Biosci, 6(D1), 1192-206.
32. Mori H, Yamada Y, Kuno T, et al (2004). Aberrant crypt foci and beta-catenin accumulated crypts: significance and roles for colorectal carcinogenesis. Mutat Res, 566, 191-208.
33. Ohno K, Narushima S, Takeuchi S, et al (2001). Effect of bacterial metabolism in the intestine on colorectal tumors induced by 1,2-dimethylhydrazine in transgenic mice harboring human prototype C-Ha- ras genes. J Exp Clin Cancer Res, 20, 51-6.
34. O'Leary KE, Cruess DG, Pleau D, et al (2011).Sex differences in associations between psychosocial factors and aberrant crypt foci among patients at risk for colon cancer. Gend Med, 8, 165-71
35. Patlolla JM, Zhang Y, Li Q (2011). Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats. Int J Oncol, 28, ??.
36. Paulsen JE (2000). Modulation by dietary factors in murine FAP models. Toxicol Lett, 112-113, 403-9.
37. Pera SA, Bird RP (1992). Expression of ras oncogene mRNA and protein in aberrant crypt foci. Carcinogenesis, 13, 1863-8.
38. Pretlow TP, Cheyer C, O'Riordan MA (1994). Aberrant crypt foci and colon tumors in F344 rats have similar increases in proliferative activity. Int J Cancer, 56, 599-602.
39. Rao CV, Rivenson A, Simi B, Zang E, et al (1995). Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res, 55, 1464-72.
40. Reis CA, David L, Nielscn PA, et al (1997). Immunohistochemical study of MUC5 expression in human gastric carcinomas using a novel monoclonal antibody. Int J Cancer, 74, 112-21.
41. Roncucci L, Medline A, Bruce WR (1991). Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol Biomarkers Prev, 1, 57-60.
42. Salim EI (2005). Ultrastructure and gene profiling analysis on aberrant crypt foci and tumors from colon of rats treated with 1,2-Dimethylhydrazine. Egypt J Zool, 44, 389-420.
43. Salim EI (2006). Molecular alterapttions in mucin genes expression and histochemical properties of mucosa during rat colon carcinogenesis. J Egypt Ger Soci Zool, 33, 68-76.
44. Seike K, Koda K, Oda K, et al (2006). Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol, 101, 1362-9.
45. Sengottuvelan M, Viswanathan P, Nalini N (2007). Chemopreventive effect of trans-resveratrol-a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis, 27, 1038-46.
46. Serraino M, Thompson LU (1992). Flaxseeds supplementation and early markers of colon carcinogenesis. Cancer Lett, 63, 159-65.
47. Shen J, Wanibuchi H, Salim EI (2003). Induction of glutathione S-transferase placental form-positive foci in liver and epithelial hyperplasia in urinary bladder, but no tumor development in male Fischer 344 rats treated with monomethylarsonic acid for 104 weeks. Toxicol Applied Pharmacol, 193, 335-45.
48. Shivji KK, Kenny MK, Wood RD (1992). Proliferating cell nuclear antigen is required for DNA excision repair. Cell, 69, 367-74.
49. Shpitz B, Bomstein Y, Mekori Y, et al (1998). Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol, 29, 469-75.
50. Sylvester PA, Myerscough N, Warren BR, et al (2001). Differential expression of the chromosome 11 mucin genes in colorectal cancer. J Pathol, 195, 327-35.
51. Tang ZC, Shivapurkar N, Frost A, et al (1996). The effect of dietary fat on the promotion of mammary and colon cancer in a dual organ rat carcinogenesis model. Nutr Cancer, 25, 151-9.
52. Vivona AA, Shpitz B, Medline A, et al (1993). K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis, 14, 1777-81.
53. Wasan KM, Holtorf L, Subramanian R, et al (2001). Assessing plasma pharmacokinetics of cholesterol following oral co-administration with a novel vegetable stanol mixture to fasting rats. J Pharm Sci, 90, 23-8.
54. Zahashi M, Minamoto T, Yamashita N, et al (1993). Reduction in formation and growth of 1,2-dimethylhydrazine-induced aberrant crypt foci in rat colon by decosahexanoic acid. Cancer Res, 53, 2786-89.
55. Zuk M, Kulma A, Dymińska L, et al (2011). Flavonoid engineering of flax potentiate its biotechnological application. BMC Biotechnol, 28, 10-11.